Wuxi Biologics' TIDES revenue exceeded 5 billion yuan in the first half of the year, approaching the annual scale of last year.

On July 28, 2025, WuXi AppTec (603259.SH/2359.HK) disclosed its mid-year report for 2025. The company's highly anticipated TIDES business achieved a revenue of 5.03 billion RMB in the first half of the year, a year-on-year increase of 141.6%. At the same time, as of the end of June, TIDES' order backlog increased by 48.8% year-on-year. Due to the surge in demand in the peptide field, the current market is facing a shortage of peptide production capacity and capabilities. In 2024, WuXi AppTec's TIDES business achieved a revenue of 5.8 billion RMB.